CD73 antibody (full length) (Biotin)

Catalog No. ABIN7877582

This Mouse Monoclonal antibody specifically detects CD73 in WB, FACS, IF, ELISA and IHC (p). It exhibits reactivity toward Human.

Quick Overview for CD73 antibody (full length) (Biotin) (ABIN7877582)

Target: CD73 (NT5E) (5'-Nucleotidase, Ecto (CD73) (NT5E))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This CD73 antibody is conjugated to Biotin

Application: Western Blotting (WB), Flow Cytometry (FACS), Immunofluorescence (IF), ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: NT5E-2646

Product Details anti-CD73 Antibody (Biotin)

Binding Specificity: full length

Purpose: CD73 Antibody

Purification: Protein G affinity chromatography

Immunogen: Recombinant full-length human NT5E protein was used as the immunogen for the CD73 antibody.

Isotype: IgG1, kappa

Application Details

Application Notes: Optimal dilution of the CD73 antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: 0.1 mg/mL with 0.1 mg/mL BSA (US sourced), 0.05 % sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Store the CD73 antibody at 2-8oC (up to one month) or aliquot and store at -20oC (longer term).

Target Details for CD73

Target: CD73 (NT5E) (5'-Nucleotidase, Ecto (CD73) (NT5E))

Alternative Name: CD73

Background: CD73 is a membrane-bound extracellular enzyme overexpressed in several cancer types. Its expression has been linked to poor prognosis in melanoma, colorectal, gastric, triple negative breast cancer, and to a pro-metastatic phenotype in prostate cancer. Together with CD39, it plays a major role in promoting immunosuppression through the pathway degrading adenosine triphosphate (ATP) into adenosine. Within the tumor microenvironment, ATP promotes immune cell-mediated killing of cancer cells. In contrast, adenosine accumulation causes immune suppression, dysregulation of immune cell infiltrates and stimulates angiogenesis resulting in tumor spreading. CD73 is active on the last step of the degradation pathway, where it is the enzyme that actually degrades AMP into adenosine. CD73-blockade promotes anti-tumor immunity by reducing adenosine accumulation. Accordingly, anti-CD73 mAbs stimulate anti-tumor immunity and reduce tumor metastasis in mouse tumor models, and could enhance the efficacy of treatment with anti-PD1 or anti-CTLA4 antibodies.

UniProt: P21589

Pathways: Synaptic Membrane, Ribonucleoside Biosynthetic Process